Literature DB >> 25644161

Prostate cancer: Predicting prostate biopsy results--PCA3 versus phi.

Stacy Loeb1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25644161     DOI： 10.1038/nrurol.2015.1

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  8 in total

1.  A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range.

Authors:  William J Catalona; Alan W Partin; Martin G Sanda; John T Wei; George G Klee; Chris H Bangma; Kevin M Slawin; Leonard S Marks; Stacy Loeb; Dennis L Broyles; Sanghyuk S Shin; Amabelle B Cruz; Daniel W Chan; Lori J Sokoll; William L Roberts; Ron H N van Schaik; Isaac A Mizrahi
Journal:  J Urol       Date:  2011-03-17       Impact factor: 7.450

2.  Accuracy of the prostate health index versus the urinary prostate cancer antigen 3 score to predict overall and significant prostate cancer at initial biopsy.

Authors:  Thomas Seisen; Morgan Rouprêt; Didier Brault; Priscilla Léon; Géraldine Cancel-Tassin; Eva Compérat; Raphaële Renard-Penna; Pierre Mozer; Jérome Guechot; Olivier Cussenot
Journal:  Prostate       Date:  2014-10-18       Impact factor: 4.104

3.  Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program.

Authors:  Jeffrey J Tosoian; Stacy Loeb; Anna Kettermann; Patricia Landis; Debra J Elliot; Jonathan I Epstein; Alan W Partin; H Ballentine Carter; Lori J Sokoll
Journal:  J Urol       Date:  2009-12-14       Impact factor: 7.450

4.  Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer.

Authors:  Jeffrey J Tosoian; Stacy Loeb; Zhaoyong Feng; Sumit Isharwal; Patricia Landis; Debra J Elliot; Robert Veltri; Jonathan I Epstein; Alan W Partin; H Ballentine Carter; Bruce Trock; Lori J Sokoll
Journal:  J Urol       Date:  2012-08-15       Impact factor: 7.450

5.  Multicenter European external validation of a prostate health index-based nomogram for predicting prostate cancer at extended biopsy.

Authors:  Giovanni Lughezzani; Massimo Lazzeri; Alexander Haese; Thomas McNicholas; Alexandre de la Taille; Nicolò Maria Buffi; Nicola Fossati; Giuliana Lista; Alessandro Larcher; Alberto Abrate; Alessandro Mistretta; Vittorio Bini; Joan Palou Redorta; Markus Graefen; Giorgio Guazzoni
Journal:  Eur Urol       Date:  2013-12-16       Impact factor: 20.096

Review 6.  Prostate health index vs percent free prostate-specific antigen for prostate cancer detection in men with "gray" prostate-specific antigen levels at first biopsy: systematic review and meta-analysis.

Authors:  Dario Bruzzese; Claudia Mazzarella; Matteo Ferro; Sisto Perdonà; Paolo Chiodini; Giuseppe Perruolo; Daniela Terracciano
Journal:  Transl Res       Date:  2014-06-26       Impact factor: 7.012

7.  Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study.

Authors:  Daniel W Lin; Lisa F Newcomb; Elissa C Brown; James D Brooks; Peter R Carroll; Ziding Feng; Martin E Gleave; Raymond S Lance; Martin G Sanda; Ian M Thompson; John T Wei; Peter S Nelson
Journal:  Clin Cancer Res       Date:  2013-03-20       Impact factor: 12.531

8.  Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml.

Authors:  Matteo Ferro; Dario Bruzzese; Sisto Perdonà; Ada Marino; Claudia Mazzarella; Giuseppe Perruolo; Vittoria D'Esposito; Vincenzo Cosimato; Carlo Buonerba; Giuseppe Di Lorenzo; Gennaro Musi; Ottavio De Cobelli; Felix K Chun; Daniela Terracciano
Journal:  PLoS One       Date:  2013-07-04       Impact factor: 3.240
  8 in total
  5 in total

Review 1.  Emerging impact of the long noncoding RNA MIR22HG on proliferation and apoptosis in multiple human cancers.

Authors:  Le Zhang; Cuixia Li; Xiulan Su
Journal:  J Exp Clin Cancer Res       Date:  2020-12-03

Review 2.  Virus encoded circulatory miRNAs for early detection of prostate cancer.

Authors:  Jayoung Kim; Seok Joong Yun; Wun-Jae Kim
Journal:  BMC Urol       Date:  2015-11-26       Impact factor: 2.264

3.  Performance of the Prostate Health Index in predicting prostate biopsy outcomes among men with a negative digital rectal examination and transrectal ultrasonography.

Authors:  Guo-Peng Yu; Rong Na; Ding-Wei Ye; Jun Qi; Fang Liu; Hai-Tao Chen; Yi-Shuo Wu; Gui-Ming Zhang; Jie-Lin Sun; Yao Zhu; Li-Qun Huang; Shan-Cheng Ren; De-Ke Jiang; S Lilly Zheng; Hao-Wen Jiang; Ying-Hao Sun; Qiang Ding; Jianfeng Xu
Journal:  Asian J Androl       Date:  2016 Jul-Aug       Impact factor: 3.285

4.  Advances in Biomarkers for PCa Diagnostics and Prognostics-A Way towards Personalized Medicine.

Authors:  Carsten Stephan; Klaus Jung
Journal:  Int J Mol Sci       Date:  2017-10-20       Impact factor: 5.923

Review 5.  Clinical Applications of Molecular Biomarkers in Prostate Cancer.

Authors:  Felipe Couñago; Fernando López-Campos; Ana Aurora Díaz-Gavela; Elena Almagro; Esaú Fenández-Pascual; Iván Henríquez; Rebeca Lozano; Estefanía Linares Espinós; Alfonso Gómez-Iturriaga; Guillermo de Velasco; Luis Miguel Quintana Franco; Ignacio Rodríguez-Melcón; José López-Torrecilla; Daniel E Spratt; Luis Leonardo Guerrero; Juan Ignacio Martínez-Salamanca; Elia Del Cerro
Journal:  Cancers (Basel)       Date:  2020-06-12       Impact factor: 6.639
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.